Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap Down - Here's What Happened

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) gapped down prior to trading on Monday . The stock had previously closed at $21.67, but opened at $20.77. Dianthus Therapeutics shares last traded at $21.59, with a volume of 14,201 shares traded.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on DNTH shares. HC Wainwright reiterated a "buy" rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Wedbush reaffirmed an "outperform" rating and issued a $36.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Finally, Guggenheim reissued a "buy" rating and issued a $84.00 price target on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Seven analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $54.33.

Dianthus Therapeutics Price Performance

The business's fifty day moving average price is $19.86 and its 200 day moving average price is $22.78. The stock has a market cap of $692.80 million, a P/E ratio of -8.67 and a beta of 1.62.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its quarterly earnings results on Tuesday, March 11th. The company reported ($0.81) EPS for the quarter, beating analysts' consensus estimates of ($0.85) by $0.04. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The company had revenue of $1.33 million during the quarter, compared to analysts' expectations of $1.40 million. On average, analysts predict that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. R Squared Ltd acquired a new stake in Dianthus Therapeutics during the 4th quarter worth about $26,000. KLP Kapitalforvaltning AS acquired a new position in Dianthus Therapeutics in the fourth quarter valued at approximately $33,000. KBC Group NV bought a new position in shares of Dianthus Therapeutics during the 4th quarter worth approximately $35,000. BNP Paribas Financial Markets bought a new stake in shares of Dianthus Therapeutics in the 4th quarter valued at $59,000. Finally, GAMMA Investing LLC boosted its stake in Dianthus Therapeutics by 3,030.6% during the first quarter. GAMMA Investing LLC now owns 3,882 shares of the company's stock worth $70,000 after acquiring an additional 3,758 shares in the last quarter. Institutional investors own 47.53% of the company's stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.